SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-23-000380
Filing Date
2023-03-24
Accepted
2023-03-24 16:43:06
Documents
2
Group Members
ORBIMED ADVISORS ISRAEL II LTDORBIMED CAPITAL GP VI LLCORBIMED ISRAEL GP II, L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 ss1901398_sc13da.htm SC 13D/A 117332
2 JOINT FILING AGREEMENT ss1901398_ex9901.htm EX-99.1 7526
  Complete submission text file 0000947871-23-000380.txt   126489
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104
Business Address 142 SANSOME STREET SECOND FLOOR SAN FRANCISCO CA 94104 (415) 432-9270
89bio, Inc. (Subject) CIK: 0001785173 (see all company filings)

IRS No.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91200 | Film No.: 23760417
SIC: 2834 Pharmaceutical Preparations